Pegtarviliase ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 337 | ホモシスチン尿症 | 1 |
337. ホモシスチン尿症
臨床試験数 : 16 / 薬物数 : 19 - (DrugBank : 7) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05154890 (ClinicalTrials.gov) | May 13, 2021 | 20/8/2021 | A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency | A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine ß-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177 | Homocystinuria Due to Cystathionine Beta-Synthase Deficiency | Drug: Pegtarviliase | Aeglea Biotherapeutics | NULL | Recruiting | 12 Years | N/A | All | 36 | Phase 1/Phase 2 | United States;Australia;United Kingdom |